Trial Profile
A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 28 Mar 2019
Price :
$35
*
At a glance
- Drugs Staphylococcal-protein-A (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Protalex
- 21 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 12 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
- 17 Jun 2018 Results from the first four dosing cohorts (n=13) presented at the 23rd Congress of the European Haematology Association